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Mariet C.W. Feltkamp2 and Jan Nico Bouwes Bavinck1
Organ transplant recipients (OTRs) have an increased risk of developing keratinocyte carcinomas (KCs). The aim
of this study was to correlate infection with human papillomaviruses (HPVs) belonging to the beta genus (Beta-
papillomavirus (Beta-PV)) at transplantation with later development of KCs. In a cohort study, sera collected
between 1 year before and 1 year after transplantation of OTRs transplanted between 1990 and 2006 were tested
for antibody responses against the L1 capsid antigen of Beta-PV and other HPV genera (Gamma-, Mu-, Nu-, and
Alpha-PV) using multiplex serology. The OTRs were followed for a maximum of 22 years. Cox regression models
with KC, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) as outcome variables were used. Out of
445 OTRs, 60 had developed KC: 14 developed only SCC, 24 only BCC, and 22 both types of KC. The time-
dependent hazard ratio (HR) to develop either or both types of KC, adjusted for age, sex, and transplanted organ,
in tested Beta-PV-seropositive OTR around the time of transplantation compared with Beta-PV-seronegative OTR
was 2.9 (95% confidence interval (CI) 1.3–6.4). The HR for SCC was 2.9 (95% CI 0.99–8.5) and for BCC it was 3.1
(95% CI 1.2–8.0). There was also an association between Mu-PV seropositivity and KC, but there were no
significant associations between other HPV genera tested and KC. A positive seroresponse for Beta-PV around
transplantation significantly predicted the development of KC in OTRs up to 22 years later, providing additional
evidence that infection with Beta-PV has a role in KC carcinogenesis.
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INTRODUCTION
Keratinocyte carcinomas (KCs) are the most prevalent malig-
nancies seen in organ transplant recipients (OTRs). The
incidence of squamous cell carcinoma (SCC) is 60–250 times
increased compared with the general population, and for
basal cell carcinomas (BCCs) this is 10–40 times (Hartevelt
et al., 1990; Euvrard et al., 2003; Moloney et al., 2006; Tessari
et al., 2010). In OTRs, SCCs are more frequently observed
than BCC, with a SCC/BCC ratio of 5:1 compared with the
general population where a SCC/BCC ratio of 1:4 is found
(Wisgerhof et al., 2009).
Life-long immunosuppressive therapy is the most important
risk factor for developing KCs in OTRs. Other important risk
factors include sun exposure, male gender, older age, smoking,
and fair skin with susceptibility to sunburn. These are similar
risk factors as in the immunocompetent population (Terhorst
et al., 2009). A role of human papillomaviruses (HPVs) in the
development of KC has also been frequently suggested (Proby
et al., 2011; Andersson et al., 2012; Neale et al., 2013).
HPVs are small double-stranded DNA viruses that infect
epithelia of the skin or mucosa. Over 150 different types have
been described (de Villiers et al., 2004; Bernard et al., 2010).
HPV has been estimated to have a causative role in 5.2% of all
human cancers (Parkin, 2006). HPV types are classified in
different classes (1–4) by the IARC (International Agency for
Research on Cancer) based on their carcinogenic potential
(IARC, 2007; Bouvard et al., 2009).
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The first time that HPV infection was linked with KC
was in patients with a rare autosomal recessive disease
called epidermodysplasia verruciformis (Jablonska et al.,
1972). Patients with epidermodysplasia verruciformis have
an increased susceptibility to widespread Beta-papillomavirus
(Beta-PV) infections of the skin that progress to SCC in one-
third of the patients, mainly on sun-exposed sites (Lutzner,
1978). In the years after transplantation, OTRs start to
develop a clinical picture that resembles that of patients
with epidermodysplasia verruciformis. Epidemiological and
experimental data have advocated a potential carcinogenic
role of cutaneous HPV infection in skin cancer, especially of
SCC in the immunosuppressed population (Bouwes Bavinck
et al., 2008).
There are different methods to detect Beta-PV infection,
based on measurement of viral protein, viral DNA, or serum
antibody responses (Aldabagh et al., 2013). Serological
responses are considered as the most consistent marker of
biologically relevant Beta-PV infection (Andersson et al.,
2012), reflecting a past or present infection strong enough to
evoke an immune response.
Most studies investigating the association between sero-
logical responses to HPV and SCC are cross-sectional or case–
control studies that were carried out in the immunocompetent
population, and showed an association between detection of
Beta-PV antibodies and SCC (Feltkamp et al., 2003; Karagas
et al., 2006; Waterboer et al., 2008; Karagas et al., 2010;
Bzhalava et al., 2013). As far as we know, cohort studies
investigating the association between serological responses to
HPV and later development of a first KC were not carried out
in OTR (Aldabagh et al., 2013). Therefore, we designed a
retrospective follow-up study to establish whether there is a
relationship between the presence of serological responses to
HPV, in particular Beta-PV, around transplantation and the
development of KC (SCC and BCC) in the years after the organ
transplantation.
RESULTS
The baseline characteristics of the 445 OTRs included in the
study are shown in Table 1. The majority of patients were
male (65%) and most patients (79%) underwent kidney
transplantation. The mean age of the patients at transplanta-
tion was 47.3 years and the mean follow-up after transplanta-
tion was 11.8 year. A mean of 4.2 sera (range 1–17) was
available from 1 year before to 1 year after transplantation.
Among the patients who developed KC, the mean time from
transplantation until the first KC was 7.7 years.
Supplementary Table S1 online shows the percentages of
OTRs who were seropositive for any HPV type tested between
1 year before and 1 year after the transplantation, for all
OTRs together and stratified for those with KC, SCC, and
BCC. Table 2 summarizes Supplementary Table S1 online and
provides the percentages of OTRs who were seropositive for at
least one HPV type per HPV genus (Beta-, Gamma-, Mu-, Nu,
or Alpha-PV). Seroresponses against the beta genus were
more frequently observed in the patients with KC compared
with patients without KC, reaching statistical significance
(P¼ 0.005; Table 2). Patients who were seropositive for at
least one HPV type of a specific genus had a greater prob-
ability for being seropositive for another HPV genus (Supple-
mentary Table S2 online).
The cumulative incidence of KC in Beta-PV-seronegative
and Beta-PV-seropositive OTR is depicted in Figure 1 and
Supplementary Figure S1 online. Log-rank tests were
performed and showed a significant difference between Beta-
PV-seropositive and -seronegative OTRs (P¼0.043). The
Kaplan-Meier plots for SCC and BCC showed similar curves
as the plots for KC (Supplementary Figures S2 and S3 online).
Table 3 shows the time-dependent nonadjusted hazard ratios
(HRs) and the HRs adjusted for age at transplantation, sex, and
type of transplantation for the development of KC, SCC, and
BCC. A positive association was found between seropositivity
for at least one Beta-PV type detected between 1 year before
and 1 year after the organ transplantation and the develop-
ment of KC, SCC, and/or BCC. After adjustment, Mu-PV
seropositivity was also associated with KC (Table 3). The
Cox proportional hazard analyses (Table 3) and the Kaplan-
Meier plots of cumulative incidence of KC, SCC, and/or BCC
in HPV-seronegative and -seropositive OTRs for the other HPV
genera tested (Gamma-, Nu-, and Alpha-PV) showed no
significant association between seropositivity against any of
these HPV genera (Supplementary Figures S1–3 online).
Beta-PV species 1 (specifically HPV8 and HPV20) and Beta-
PV species 3 (specifically HPV75 and HPV76) were most
relevant for the positive association between Beta-PV seropo-
sitivity and the development of KC (Supplementary Figure S4
online). The potential importance of these Beta-PV types was
confirmed for HPV8 and HPV75 by conditional step forward
regression analyses, and a statistically significant negative
association was observed for HPV96 (Table 4).
Beta-PV species 1 (HPV8 and HPV20) and Beta-PV species
3 (HPV76) were also associated with the development of SCC
(Supplementary Figure S5 online), confirmed by conditional
step forward regression analyses (Table 4). A statistically
significant negative association was found for HPV24 and
HPV38 (Table 4).
Beta-PV species 2 (HPV15) and species 3 (HPV75 and
HPV76) were relevant for the development of BCC (Supple-
mentary Figure S6 online), which was confirmed in the
conditional step forward regression analyses for HPV15 and
HPV26, whereas there was a statistically significant negative
association with HPV9 (Table 4).
DISCUSSION
We have found a statistically significant association between
the development of KC, SCC, and BCC after transplantation
and antibody responses to one or more Beta-PV types,
measured in serum drawn in a window between 1 year before
and 1 year after organ transplantation. The antibody response
against Beta-PV types was specific for the beta genus, as there
were no significant associations for positive seroresponses
against the gamma, nu, and alpha genera with the develop-
ment of KC, SCC, or BCC. Interestingly, we also found
a positive association between KC and Mu-PV seropositivity,
an HPV genus not recognized previously as potentially
associated with KC development.
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So far, most studies investigating HPV seroresponses in
association with KC development concerned cross-sectional
and case–control studies in the immunocompetent population
(Aldabagh et al., 2013). We are aware of only a few published
cohort studies that were performed in the immunocompetent
population. A Scandinavian study described a weak
association for overall Beta-PV seropositivity before SCC
diagnoses, whereas a significant association was observed
for Beta-PV species 2 (odds ratio (OR)¼ 1.3, 95% confidence
interval (CI) 1.1–1.7), and for serum samples taken418 years
before diagnosis (OR¼1.8, 95% CI 1.1–2.8) (Andersson et al.,
2012). A population-based cohort study in Australia revealed
no associations between the presence of any of the Beta-PV
antibodies and the occurrence of SCC (Plasmeijer et al., 2011).
However, among people who were o50 years old in 1992,
the presence of Beta-PV antibodies was associated with a
2-fold increased risk of SCC (Plasmeijer et al., 2011). In the
United Kingdom, a prospective pilot study found no signi-
ficant differences in seropositivity of any of the 38 HPV types
(Casabonne et al., 2007). One study investigated the possible
role of seropositivity for different HPVs in the incidence of a
subsequent KC in 107 patients with a follow-up of 5 years who
were enrolled in a previous case–control study. HPV seropo-
sitivity at baseline was strongly associated with the risk of
developing a second SCC after 5 years for a number of beta
and gamma HPV types, but no association was found for
developing a second BCC (Paradisi et al., 2011). As far as we
know, our study is the first cohort study with a prolonged
follow-up period in OTRs in which the relationship between
HPV serology before and just after the organ transplantation
was studied in relation to later development of a first KC.
Proby et al. (2011) conducted a case–control study in OTRs
from The Netherlands, United Kingdom, France, and Italy to
investigate the association between SCC development and
seroresponses against Beta-PV combined with detection of
Beta-PV DNA in plucked eyebrow hairs. A positive associa-
tion was found for concordant DNA and seropositivity for
HPV36 (OR 2.4; CI 1.0–5.4), with similar, but not statistically
significant, associations for HPV5, HPV9, and HPV24. Con-
cordant Beta-PV DNA presence in hair and a serological
antibody response for at least one HPV type was significantly
associated with SCC risk (OR 1.6; CI 1.1–2.5). Another case–
control study conducted in immunocompetent patients in
Florida, USA, revealed a positive association between sero-
positivity to increasing numbers of Beta-PV types and SCC
(OR 1.9; 95% CI 1.2–3.0) (Iannacone et al., 2012). A similar
association for Beta-PV types DNA in eyebrow hairs was
found in another clinic-based case–control study (4 types vs.
HPV-negative: OR 2.0, 95% CI 1.1–3.8) (Iannacone et al.,
2014). Waterboer et al. (2008) performed a case–control study
in an Italian immunocompetent population and found a
significant 2- to 3-fold risk of SCC with seropositivity for any
species 2 Beta-PV type (OR 3.3, 95% CI 1.2–8.7) and for the
Gamma-PV types (OR 3.1, 95% CI 1.1–8.6). In a multinational
case–control study in immunocompetent subjects, a positive
antibody response against four or more Beta-PV types was
associated with a doubled risk for SCC in Australia and the
Netherlands (Bouwes Bavinck et al., 2010).
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Little data are published about the association between HPV
infection and the development of BCC and the findings are
contradictory. A relationship between seroresponses to Beta-
PV and the development of BCC has been described pre-
viously (Steger et al., 1990; Stark et al., 1998; Feltkamp et al.,
2003; Andersson et al., 2012). Interestingly, Paolini et al.
(2011) reported a high frequency (11.5%) of HPV15 DNA
in a small cohort of BCC patients, in agreement with the
observed positive association between HPV15 and BCC in our
study. However, some other studies did not report a positive
association between Beta-PV seroreactivity and BCC (Karagas
et al., 2006; Andersson et al., 2008; Karagas et al., 2010;
Iannacone et al., 2013). A recent systematic review showed
no association between Beta-PV serological responses and
BCC (Bzhalava et al., 2013). In a subgroup of patients in
Florida, USA, with Beta-PV DNA-positive BCC, however,
an association between a serological response against
Beta-PV and BCC was observed (Iannacone et al., 2013). In
a population-based case–control study of patients with
SCC, BCC, and controls from New Hampshire, USA, it was
found that seropositivity to Beta-PV (OR 1.5, 95% CI 1.0–2.1)
was significantly associated with SCC. This risk increased
with positivity for multiple HPV types. No associations were
found with BCC risk (Karagas et al., 2006). Karagas et al.
(2010) confirmed these findings in a larger group of
2366 skin cancer cases and controls. We cannot exclude,
however, that the OTRs who developed BCC in our
study are at increased risk of developing SCC later on,
because BCCs often precede the development of SCC in
these patients.
Table 2. Numbers and percentages of organ transplant recipients with positive antibody responses against one or
more human papillomavirus (HPV) types of different HPV genera1
Keratinocyte
carcinoma
Squamous cell carcinoma, irrespective
of basal cell carcinoma
Basal cell carcinoma, irrespective
of squamous cell carcinoma
All patients
þ  þ  þ 
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Any Beta-HPV
Negative 119 (26.7) 7 (11.7) 112 (29.1) 4 (11.1) 115 (28.1) 5 (10.9) 114 (28.6)
Positive 326 (73.3) 53 (88.3) 273 (70.9) 32 (88.9) 294 (71.9) 41 (89.1) 285 (71.4)
Any Gamma-HPV
Negative 113 (25.4) 12 (20.0) 101 (26.2) 6 (16.7) 107 (26.2) 10 (21.7) 103 (25.8)
Positive 332 (74.6) 48 (80.0) 284 (73.8) 30 (83.3) 302 (73.8) 36 (78.3) 296 (74.2)
Any Mu-HPV
Negative 151 (33.9) 12 (20.0) 139 (36.1) 6 (16.7) 145 (35.5) 9 (19.6) 142 (35.6)
Positive 294 (66.1) 48 (80.0) 246 (63.9) 30 (83.3) 264 (64.5) 37 (80.4) 257 (64.4)
Any Nu-HPV
Negative 367 (82.5) 46 (76.7) 321 (83.4) 27 (75.0) 340 (83.1) 37 (80.4) 330 (82.7)
Positive 78 (17.5) 14 (23.3) 64 (16.6) 9 (25.0) 69 (16.9) 9 (19.6) 69 (17.3)
Any Alpha-HPV
Negative 106 (23.8) 13 (21.7) 93 (24.2) 8 (22.2) 98 (24.0) 10 (21.7) 96 (24.1)
Positive 339 (76.2) 47 (78.3) 292 (75.8) 28 (77.8) 311 (76.0) 36 (78.3) 303 (75.9)
1HPV types tested were: 7 Alpha-HPV (HPVs 2, 3, 6, 7, 13, 16, and 27b), 16 Beta-HPV (HPVs 5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 93, and 96), 8
Gamma-HPV (HPVs 4, 48, 50, 60, 65, 95, 101, and 103), 2 Mu-HPV (HPV1 and HPV63), and 1 Nu-HPV (HPV41).
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Figure 1. Kaplan–Meier plot for development of keratinocyte carcinomas
(KCs) in relation to human papillomavirus (HPV) serology. The cumulative
incidence of keratinocyte carcinomas (KCs) is statistically significantly higher in
organ transplant recipients (OTRs) who were seropositive against one or more
HPV types of the Beta-papillomavirus (Beta-PV) genus between 1 year before
and 1 year after the transplantation (P¼0.043).
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Besides the advantages, the retrospective design of our
study also has some disadvantages. For instance, the sera we
tested were not systematically collected with the purpose to
study a relationship with KC but were randomly selected from
routinely archived sera collected for HLA antibody screening
and other diagnostic purposes. The HRs we calculated were
adjusted for sex, age at transplantation, and type of trans-
plantation (Wisgerhof et al., 2009). We could not adjust for
other risk factors for KC, like sun exposure, sunburns, skin
type, and type of immunosuppression, because these data
were not systematically collected for all patients. These risk
factors are associated with an increased prevalence of HPV
DNA in eyebrow hairs, but it is not known whether this is
also the case for Beta-PV seroresponses (Alotaibi et al., 2006;
Chen et al., 2008; de Koning et al., 2009).
A drawback of our study was that data about seroconversion
were not systematically available. It can be speculated that
seroconversion in the years following transplantation in OTRs
who were seronegative around transplantation might have
increased the risk of tumor development in the seronegative
group that, if true, could have led to a stronger association
between Beta-PV-type seropositivity and KC.
In general, a drawback of studies reporting the association
between serological responses and skin cancer is that because
of differences in the employed methodologies (initially starting
with western blotting, followed by HPV-type-specific ELISAs
using L1 virus-like particles, and more recently by high-
throughput multiplex fluorescent bead–based assays enabling
the simultaneous detection of antibody responses in large
series of serologic samples against a variety of HPVs) the
outcomes between the different studies cannot always be
reliably compared. In our study, however, this is only true for
the earlier studies referred to (western blot by Steger et al.,
1990 and ELISA technique by Stark et al., 1998; Feltkamp
et al., 2003), as the other studies all used the same multiplex
serology technique that was performed in the same labo-
ratory in Heidelberg. Other factors that may explain the
different associations between HPV infection and KC are
differences in immunosuppressive regimens between centers
that may exert different effects on the present HPV types,
different exposure to sunlight reflected by the different
latitudes of the centers, and differences in exposure to
different HPV types.
The exact mechanism by which Beta-PV infection predis-
poses for the development of KC remains unclear. It has been
hypothesized that the effects of the virus on UV-induced DNA
damage withholds apoptosis and DNA repair by accumulation
of mutations (Bouwes Bavinck and Feltkamp, 2004). This is
supported by the fact that the E6 and E7 proteins from Beta-PV
types are capable of inhibiting UV-induced cell cycle
checkpoints and DNA repair mechanisms (Jackson et al.,
2000; Jackson and Storey, 2000; Struijk et al., 2008;
Underbrink et al., 2008). This potentially deregulates cell
cycle control and growth in keratinocytes (zur Hausen, 1999;
Iannacone et al., 2012). Some Beta-PV types could upregulate
the p16INK4a and Akt/P13K pathway and might have a role
in the carcinogenesis of BCC (Paolini et al., 2011). The
epidemiological evidence that HPV is involved in BCC
carcinogenesis, however, is much weaker compared with
the possible involvement of HPV in cutaneous SCC carcino-
genesis. In conclusion, a detectable seroresponse for one or
more Beta-PV types around the time of transplantation
predicts an increased risk for the development of KC in
OTR. This study provides additional evidence that infection
with Beta-PV types has a role in keratinocyte carcinogenesis.
Additional studies will be necessary to confirm the observed
association between Mu-PV infection and KC development.
MATERIALS AND METHODS
Study design
Between 1966 and 2006, a total of 2,136 patients were transplanted
in the Leiden University Medical Center (LUMC) (Supplementary
Figure S2 online). OTRs consisted of both kidney transplant recipients
and simultaneous pancreas–kidney transplant recipients.
During the past 25 years, sera were collected from a considerable
number of OTRs. The most extensive source of sera consisted of
samples collected from 1989 for clinical care–related screening and
diagnostic purposes that were systematically stored in the Department
Table 3. Time-dependent Cox proportional hazard ratios for keratinocyte carcinoma, squamous cell carcinoma, and
basal cell carcinoma in organ transplant recipients related to human papillomavirus (HPV) genus serostatus between
1 year before and 1 year after the transplantation
Keratinocyte
carcinoma
Squamous cell carcinoma, irrespective
of basal cell carcinoma
Basal cell carcinoma, irrespective
of squamous cell carcinoma
Unadjusted
hazard ratio
Adjusted1
hazard ratio
Unadjusted
hazard ratio
Adjusted1
hazard ratio
Unadjusted
hazard ratio
Adjusted1
hazard ratio
Beta-HPV 2.2 (1.0–4.9) 2.8 (1.3–6.4) 2.1 (0.75–6.1) 2.9 (0.99–8.5) 2.3 (0.92–6.0) 3.1 (1.2–8.0)
Gamma-HPV 1.1 (0.59–2.1) 1.3 (0.66–2.4) 1.2 (0.51–3.0) 1.7 (0.68–4.1) 0.97 (0.48–2.0) 1.1 (0.54–2.2)
Mu-HPV 1.8 (0.95–3.4) 2.0 (1.0–3.7) 2.1 (0.86–5.0) 2.4 (0.98–5.7) 1.8 (0.86–3.7) 1.9 (0.93–4.0)
Nu-HPV 1.2 (0.68–2.2) 1.5 (0.80–2.7) 1.3 (0.61–2.7) 1.8 (0.84–4.0) 1.0 (0.46–2.0) 1.1 (0.53–2.3)
Alpha-HPV 0.93 (0.50–1.7) 0.99 (0.53–1.8) 0.84 (0.38–1.9) 0.97 (0.44–2.2) 0.92 (0.46–1.9) 0.97 (0.48–2.0)
1Adjusted for sex, age at transplantation, and type of transplantation.
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of Medical Microbiology of the LUMC. In the scope of earlier case–
control studies, additional sera had been collected and stored
(Bouwes Bavinck et al., 1991; Bouwes Bavinck et al., 1993). From
the 101 patients who participated in a prospective study (Antonsson
et al., 2013), pretransplant sera were retraced from the Eurotransplant
serumbank. Altogether, 7,912 sera were available from 1,269 OTRs
(Supplementary Figure S2 online). Because of practical reasons we
had to limit the number of sera to be tested to a maximum of 3,000,
the number thought to provide enough statistical power to answer our
questions.
We selected 648 representative sera from all 164 OTRs who
developed KC during follow-up for whom at least one serum sample
was available. For each of these OTRs, we selected between 3 and 5
control OTRs without skin cancer. These patients were matched for
type of transplantation (kidney transplant recipients or simultaneous
pancreas–kidney transplant recipients), sex, and age at transplanta-
tion, resulting in the selection of 2,112 sera from 534 OTRs
without skin cancer (Supplementary Figure S2 online). These sera
had been collected between 7 years before and 42 years after the
transplantation.
As we were specifically interested in the association between
seroresponses to HPV around the transplantation and the later
development of KC, we further restricted our selection to OTRs
who had sera collected between 1 year before and 1 year after the
transplantation. This resulted in a final cohort consisting of 1,880 sera
from 445 OTRs, of whom 60 had developed KC (14 only SCC, 24
only BCC, and 22 both types of skin cancer) during the 22-year
follow-up period. The number of sera collected in these patients
ranged from 1 to 11 (mean: 4.2, median: 4.0). The remaining sera will
be analyzed in a separate study.
Data about development of KC were retracted from the LUMC
oncologic database, the LUMC pathology database, and by hand
searching of the medical files. The study was approved by the
medical ethical committee of the LUMC.
Table 4. Association between 16 different Beta-papillomavirus (Beta-PV) types and skin cancer
Keratinocyte carcinoma Squamous cell carcinoma Basal cell carcinoma
All variables in the
regression model1
Forward regression
final model
All variables in the
regression model
Forward regression
final model
All variables in the
regression model
Forward regression
final model
Species 1
HPV5 1.3 (0.57; 3.1) 1.7 (0.54; 5.1) 1.2 (0.46; 3.1)
HPV8 2.6 (1.2; 5.6) 2.4 (1.3; 4.6) 3.4 (1.3; 8.8) 3.4 (1.4; 8.3) 2.2 (0.96; 5.1)
HPV20 2.6 (1.1; 5.9) 2.9 (1.1; 8.0) 2.6 (1.0; 6.6) 2.6 (1.0; 6.6)
HPV24 0.43 (0.15; 1.2) 0.19 (0.05; 0.71) 0.20 (0.07; 0.63) 0.68 (0.22; 2.1)
HPV36 0.50 (0.18; 1.4) 0.61 (0.18; 2.1) 0.40 (0.13; 1.3)
HPV93 0.48 (0.17; 1.4) 0.35 (0.09; 1.5) 0.27 (0.07; 1.1)
Species 2
HPV9 0.37 (0.13; 0.99) 0.50 (0.15; 1.7) 0.25 (0.08; 0.81) 0.29 (0.11; 0.76)
HPV15 1.5 (0.60; 3.7) 1.3 (0.38; 4.2) 2.3 (0.86; 6.2) 2.7 (1.2; 6.3)
HPV17 0.82 (0.35; 1.9) 0.72 (0.24) 0.95 (0.37; 2.4)
HPV23 1.3 (0.53; 3.3) 3.1 (1.0; 9.8) 2.4 (0.92; 6.4) 1.4 (0.53; 4.0)
HPV38 0.94 (0.38; 2.3) 0.23 (0.06; 0.83) 0.21 (0.07; 0.66) 0.86 (0.31; 2.4)
Species 3
HPV49 1.4 (0.56; 3.6) 1.9 (0.62; 5.9) 1.4 (0.48; 3.9)
HPV75 2.8 (1.1; 7.4) 3.1 (1.5; 6.6) 1.6 (0.47; 5.6) 2.2 (0.74; 6.7)
HPV76 1.8 (0.67; 4.8) 2.3 (0.70; 7.8) 2.6 (1.1; 6.5) 1.9 (0.64; 5.6) 2.9 (1.3; 6.5)
Species 4
HPV92 1.2 (0.49; 3.1) 1.5 (0.45; 4.9) 0.82 (0.28; 2.4)
Species 5
HPV96 0.41 (0.17; 1.0) 0.38 (0.18; 0.83) 0.56 (0.19; 1.7) 0.63 (0.24; 1.7)
Age2 1.0 (0.98; 1.0) 1.0 (1.0; 1.1) 1.1 (1.0; 1.1) 0.99 (0.96; 1.0)
Sex3 0.87 (0.47; 1.6) 1.4 (0.56; 3.3) 0.81 (0.40; 1.6)
Organ4 2.2 (1.1; 4.6) 2.1 (1.1; 4.0) 4.7 (1.8; 12.3) 4.9 (2.0; 12.1) 2.2 (1.0; 4.9) 2.4 (1.2; 4.7)
The bold numbers are statistically significant.
1Logistic regression model.
2Age: per year.
3Sex: men compared with women.
4Organ: combined pancreas and kidney compared with kidney.
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Serum processing and analysis
Serum samples were obtained from  20 1C freezers at the depart-
ment of Medical Microbiology. They were defrosted and pipetted in
96-well plates. Some selected serum samples were excluded from
further analysis, because either they could not be found, were not
properly centrifuged initially, or contained too little volume
(Supplementary Figure S7 online). The 96-well plates were shipped
on dry ice to the German Cancer Research Center (DKFZ; Heidelberg,
Germany) for analysis using Luminex technology (Austin, TX).
This multiplex serology technique is an antibody detection method
based on glutathione S-transferase capture ELISA in combination with
fluorescent bead technology. Positive serology cutoff points are
standardized at 200 mean fluorescence intensity targeted on anti-
bodies against major capsid antigen L1 of the various HPV types
(Waterboer et al., 2005; Michael et al., 2008). Sera were tested for 7
Alpha-PV (HPVs 2, 3, 6, 7, 13, 16, and 27b), 16 Beta-PV (HPVs 5, 8,
9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 93, and 96), 8 Gamma-
PV (HPVs 4, 48, 50, 60, 65, 95, 101, and 103), 2 Mu-PV (HPV1 and
HPV63), and one Nu-PV (HPV41).
The OTRs were considered seropositive for specific HPV genera or
specific HPV types if at least one of the sera tested between 1 year
before and 1 year after the transplantation had a positive antibody
response against these specific HPV genera or specific HPV types.
Statistical analyses
Baseline characteristics are given in percentages and simple mean
calculation. Kaplan–Meier survival analyses were used in conjunction
with multivariable Cox proportional hazard methods to calculate
corresponding HRs with 95% CIs for development of KC in relation to
HPV serology. The date of transplantation was used as opening date.
As censoring dates we used the date of diagnosis of first KC, the date
of the patient’s death, the date of last follow-up, the date lost to
follow-up, or the date of end of study (29 October 2012). Factors
considered as potential confounders were sex, type of transplantation,
and age at transplantation. The Cox models were adjusted for
these variables. As the variable of HPV seropositivity had a time
scope of 1year before and after the transplantation (starting point),
time-dependent Cox regression analyses were performed. The ana-
lyses of SCC were performed regardless of the presence of BCC
among the cases and controls and the analyses of BCC were
performed regardless of the presence of SCC among the cases
and controls.
To investigate whether there were Beta-PV types that were the
driving force causing the positive association between Beta-PV
seropositivity and the development of KC, we formed three sub-
groups: (1) patients who were seronegative for any Beta-PV type, (2)
patients who were seropositive for the specific Beta-PV type regard-
less of the other Beta-PV types, and (3) patients who were seronega-
tive for the specific Beta-PV type regardless of the other Beta-PV
types. The cumulative incidence of KC, SCC, and BCC was calculated
with Kaplan–Meier survival analyses. In addition, we performed
conditional step forward logistic regression to get a rough estimation
of which individual Beta-PV may possibly contribute to the associa-
tion between seropositivity and the development of KC, SCC, and/or
BCC. Starting with no variables in the model, all Beta-PV types, age,
sex, and type of organ were introduced into the model, starting with
the most relevant one until the addition of new variables did not
improve the model any longer.
All analyses were performed with SPSS 20.0 software (IBM SPSS
Statistics, IBM, Chicago, IL).
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